Galapagos NV : Galapagos delivers candidate drug in GSK alliance and receives milestone payment

Galapagos NV : Galapagos delivers candidate drug in GSK alliance and receives
                              milestone payment

Mechelen, Belgium; 9 January  2013 - Galapagos  NV (Euronext: GLPG)  announced 
today that it successfully  delivered a fifth  pre-clinical candidate drug  in 
its alliance  with GlaxoSmithKline  (GSK) triggering  a milestone  payment  to 

In 2006 Galapagos and GSK initiated a drug discovery and development  alliance 
to deliver disease modifying drugs for GSK's global R&D organization. In this
alliance Galapagos delivered a fifth candidate drug.

"Since the  start of  the  alliance in  2006,  Galapagos has  identified  five 
candidate drugs of which two have been in-licensed by GSK to date," said  Onno 
van de  Stolpe, CEO  of Galapagos.  "We  hope that  more programs  from  this 
alliance may enter the clinic."

About Galapagos' immuno-inflammation alliance with GlaxoSmithKline
Galapagos  and   GSK   initiated  an   alliance   to  discover   and   develop 
disease-modifying drugs  for  GSK's global  R&D  organization in  June  2006. 
Subject to achievement of certain milestone events Galapagos has the potential
to receive more  than €200  million in total  milestone payments,  plus up  to 
double-digit royalties  from GSK.  GSK  has an  exclusive option  to  further 
develop and commercialize compounds from the alliance on a worldwide basis.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of small
molecule and antibody therapies with novel modes-of-action. The Company is
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest
pipelines in biotech, with four programs in development and over 30 discovery
programs. The Galapagos Group has over 800 employees and operates facilities
in five countries, with global headquarters in Mechelen, Belgium. More info


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.